CN101631787A - 用于肥胖症治疗的三环异喹啉衍生物 - Google Patents

用于肥胖症治疗的三环异喹啉衍生物 Download PDF

Info

Publication number
CN101631787A
CN101631787A CN200880008061A CN200880008061A CN101631787A CN 101631787 A CN101631787 A CN 101631787A CN 200880008061 A CN200880008061 A CN 200880008061A CN 200880008061 A CN200880008061 A CN 200880008061A CN 101631787 A CN101631787 A CN 101631787A
Authority
CN
China
Prior art keywords
azepine
tetrahydrochysene
indoles
alkylsulfonyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880008061A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·昂布朗特
彼得·勃兰特
鲁内·林格姆
本特·林奎斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum AB
Original Assignee
Biovitrum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum AB filed Critical Biovitrum AB
Publication of CN101631787A publication Critical patent/CN101631787A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN200880008061A 2007-03-13 2008-03-13 用于肥胖症治疗的三环异喹啉衍生物 Pending CN101631787A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE07006117 2007-03-13
SE0700611 2007-03-13
US61/002,029 2007-11-05

Publications (1)

Publication Number Publication Date
CN101631787A true CN101631787A (zh) 2010-01-20

Family

ID=39462457

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880008061A Pending CN101631787A (zh) 2007-03-13 2008-03-13 用于肥胖症治疗的三环异喹啉衍生物

Country Status (10)

Country Link
US (1) US8138333B2 (cg-RX-API-DMAC7.html)
EP (1) EP2134714A1 (cg-RX-API-DMAC7.html)
JP (1) JP2010520917A (cg-RX-API-DMAC7.html)
CN (1) CN101631787A (cg-RX-API-DMAC7.html)
AU (1) AU2008225753A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0808791A2 (cg-RX-API-DMAC7.html)
CA (1) CA2679346A1 (cg-RX-API-DMAC7.html)
EA (1) EA016592B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ579360A (cg-RX-API-DMAC7.html)
WO (1) WO2008110598A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111961047A (zh) * 2020-08-19 2020-11-20 南通大学 一种6-乙氧基-3,4-二氢-2,7-萘啶-1(2h)-酮及其合成方法
CN115925658A (zh) * 2022-11-21 2023-04-07 常州佳德医药科技有限公司 一种2-氨基乙基呋喃的制备方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101653707B1 (ko) * 2008-05-29 2016-09-02 알바니 몰레큘라 리써치, 인크. 5-ht3 수용체 조절제, 이의 제조 방법, 및 그의 용도
WO2011153359A1 (en) 2010-06-04 2011-12-08 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
WO2012106448A1 (en) * 2011-02-02 2012-08-09 Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as janus kinase inhibitors
EP2824106B1 (en) * 2012-03-06 2016-11-23 Takeda Pharmaceutical Company Limited Tricyclic compound
US10675283B2 (en) 2017-03-24 2020-06-09 University Of South Florida Compositions and methods for white to beige adipogenesis
CN109180687A (zh) * 2018-08-31 2019-01-11 山东轩德医药科技有限公司 一种瑞卡帕步中间体的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795451A (fr) * 1972-02-23 1973-08-16 Pfizer Agents hypoglycemiants aza indoliques tricycliques
US3950343A (en) * 1973-11-06 1976-04-13 Ayerst, Mckenna And Harrison Ltd. Pyrroloisoquinoline derivatives
CA2194984C (en) 1994-07-26 2002-07-02 John Eugene Macor 4-indole derivatives as serotonin agonists and antagonists
US6133287A (en) * 1998-03-24 2000-10-17 Allelix Biopharmaceuticals Inc. Piperidine-indole compounds having 5-HT6 affinity
GB9820113D0 (en) 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
AU767009B2 (en) 1998-12-11 2003-10-30 Virginia Commonwealth University Selective 5-HT6 receptor ligands
KR100823908B1 (ko) 2000-10-20 2008-04-21 바이오비트럼 에이비(피유비엘) 2-, 3-, 4-, 또는 5-치환-n1-(벤젠술포닐)인돌 및 이의치료 용도
JP4390698B2 (ja) * 2002-06-05 2009-12-24 エフ.ホフマン−ラ ロシュ アーゲー Cns障害の処置のための5−ht6レセプターモジュレーターとしての1−スルホニル−4−アミノアルコキシインドール誘導体

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111961047A (zh) * 2020-08-19 2020-11-20 南通大学 一种6-乙氧基-3,4-二氢-2,7-萘啶-1(2h)-酮及其合成方法
CN115925658A (zh) * 2022-11-21 2023-04-07 常州佳德医药科技有限公司 一种2-氨基乙基呋喃的制备方法
CN115925658B (zh) * 2022-11-21 2024-02-27 常州佳德医药科技有限公司 一种2-氨基乙基呋喃的制备方法

Also Published As

Publication number Publication date
EA200970849A1 (ru) 2010-04-30
EP2134714A1 (en) 2009-12-23
BRPI0808791A2 (pt) 2017-05-02
NZ579360A (en) 2011-06-30
US20080293694A1 (en) 2008-11-27
JP2010520917A (ja) 2010-06-17
US8138333B2 (en) 2012-03-20
EA016592B1 (ru) 2012-06-29
CA2679346A1 (en) 2008-09-18
AU2008225753A1 (en) 2008-09-18
WO2008110598A1 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
EP2046741B1 (en) Indoles as 5-ht6 modulators
EP3115361B1 (en) Heterocyclic compounds, and preparation method and use thereof
AU2004281252A1 (en) Novel tetraydrospiro{piperidine-2,7' -pyrrolo(3,2-b)pyridine derivatives and novel indole derivatives useful in the treatment of 5-HT6 receptor -related disorders
US20060142269A1 (en) New compounds
CN101155804A (zh) 用于治疗精神疾病的哌嗪取代的苯并噻吩
HK1210608A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
KR20130100105A (ko) 류코트리엔 생성 억제제인 옥사디아졸
WO2008047883A1 (en) Piperazine-substituted benzothiophenes for treatment of mental disorders
US8138333B2 (en) Sulfonyl-indole derivatives
CN101273047A (zh) 作为蛋白激酶抑制剂的噻吩并[2,3-b]吡啶-5-甲腈
US7960374B2 (en) Tricyclic compounds, compositions, and methods useful in the treatment or prophylaxis of 5-HT6 receptor-related disorders
CN101253153A (zh) 作为5-HT<sub>2c</sub>受体激动剂的6-取代的2,3,4,5-四氢-1H-苯并[d]氮杂䓬
JP2008115175A (ja) 複素環化合物
JP3995404B2 (ja) ピリミジン誘導体またはその塩
WO2006062481A1 (en) New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
JP2007527890A (ja) ドーパミンd3受容体のモジュレーター(抗精神病剤)としてのテトラヒドロベンゾアゼピン誘導体
HK1134819A (en) Tricyclic isoquinoline derivatives for treatment of obesity
NZ577103A (en) 8-Sulfonyl-1,3,4,8-tetrahydro-2H-[1,4]oxazepino[6,7-e]indole derivatives and their use as 5-HT6 receptor ligands
EP1897876A2 (en) Compounds useful for the treatment of obesity, type II diabetes and CNS disorders
KR20070020373A (ko) 5-HT6 수용체-관련 장애의 치료에 유용한 신규한 테트라히드로스피로{피페리딘-2,7'-피롤로[3,2-b]피리딘} 유도체 및 신규한 인돌 유도체
HK1095587B (en) Thienopyrazoles

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1134819

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100120

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1134819

Country of ref document: HK